News | Heart Valve Technology | February 10, 2016

Chicago Bulls’ Coach Fred Hoiberg Leads New Heart Valve Patient Education Campaign

NBA head coach shares personal experience as heart valve patient, receiving an On-X Aortic Heart Valve in 2015

Fred Hoiberg, Chicago Bulls coach, On-X aortic heart valve, education campaign

Fred Hoiberg, head coach of the NBA Chicago Bulls, is launching a new campaign to help people with heart valve problems on www.heartvalvesurgery.com. Coach Hoiberg, pictured here with his family, wanted a single, life-long solution to his aortic heart valve problem, and received an On-X aortic mechanical valve from On-X Life Technologies Inc. in April 2015.

On-X Aortic Heart Valve, Fred Hoiberg, Chicago Bulls

The On-X Aortic Heart Valve from On-X Life Technologies Inc. is the only mechanical heart valve FDA-cleared to allow patients to reduce blood thinner medication to nearer normal levels.

February 10, 2016 — Fred Hoiberg, head coach of the National Basketball Assocation’s (NBA) Chicago Bulls, is launching a new patient education campaign featuring a video recounting his experience as a heart valve patient. The video premiered January 14 on www.HeartValveSurgery.com.

A 10-year NBA veteran who had played for the Indiana Pacers, Chicago Bulls and Minnesota Timberwolves, Hoiberg had open-heart surgery in April 2015 to replace his failing bicuspid aortic heart valve, a heredity structural malformation that had been causing increasing fatigue and shortness-of-breath.

The campaign, designed to help people with heart valve problems learn more about their condition and treatment options, is sponsored by On-X Life Technologies Inc., the company that made Coach Hoiberg’s aortic replacement heart valve. The full video is available here.

Hoiberg, who had an open-heart surgery a decade earlier to address life-threatening problems with an aortic aneurysm, was seeking a single, life-long solution to his aortic valve problem and agreed when his doctor recommended he receive an On-X Aortic Heart Valve.

“The On-X valve is expected to last throughout my lifetime, so I don’t have to worry about the possibility of future re-operations, which would have been likely if I’d received a tissue valve,” Hoiberg said. “I also didn’t want to put my family through all of the stress related to needing additional surgeries in the future.”

“Tissue valves last longer in older people and are less durable in younger people, and there are risks with every subsequent reoperation for valve failure,” said Marc Gerdisch, M.D., chief of cardiovascular and thoracic surgery at Franciscan St. Francis Heart Center in Indianapolis.

“If Coach Hoiberg had, at his age and physical activity level, received a tissue valve instead of the On-X aortic heart valve, he’d likely have needed another one, and even another one after that during his lifetime,” Gerdisch said, adding that most tissue valves are documented to fail structurally in 15 years or fewer in patients younger than age 60.

While some patients may choose replacement valves made of animal tissue in hopes of avoiding taking the blood-thinning medication warfarin, many patients also require warfarin therapy in order to manage their other health conditions, such as atrial fibrillation (AFib).

“I’ve heard that some people have concerns about taking blood-thinning medication after getting a mechanical valve, but it hasn’t been an issue for me. I’m very physically active, yet I haven’t had to make any major changes in either my activities or my diet because I’m taking blood-thinners,” said Hoiberg.

Gerdisch added that patients with On-X aortic heart valves are the only ones in the United States who have been allowed by the U.S. Food and Drug Administration (FDA) to reduce their blood-thinning medications to “near normal” levels.

“In a multi-year clinical study, we demonstrated that patients who had received an On-X aortic heart valve could be safely and effectively managed at much lower levels of blood thinner medication. Our findings showed that there are significant reductions in complications with the On-X valve when compared to any other valve, whether mechanical or tissue,”1 said Gerdisch, who also served as a principal investigator of the PROACT (Prospective Randomized On-X Anticoagulation Clinical Trial) study. “The On-X valve is a genuine innovation and the only mechanical valve that I implant.”

On-X replacement heart valves are bileaflet prosthetic valves made of pure pyrolytic carbon. Clinical evaluations have shown that the On-X Aortic Heart Valve features a unique material and design, which have been clinically documented to have lower complications than other mechanical heart valves.

For more information: www.onxvalve.com

Related Content

Stem Cell Therapy May Offer Treatment for Rare Congenital Cardiac Defect
News | Congenital Heart | February 05, 2018
February 5, 2018 — Children's Hospital Los Angeles announced participation in the first-ever...
Screening for Critical Congenital Heart Disease at Birth Saves Lives
News | Congenital Heart | December 05, 2017
Infant deaths from critical congenital heart disease (CCHD) decreased more than 33 percent in eight states that...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart | September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
AHA and ACC Publish New Data Dictionary for Ambulatory EHRs in Pediatric and Congenital Cardiology
News | Congenital Heart | July 19, 2017
July 19, 2017 — The American Heart Association (AHA) and the American College of Cardiology (ACC) recently published
New Multi-Center Research Effort to Focus on Early Life Origins of Heart Health
News | Congenital Heart | June 23, 2017
Heart health in children will be the focus of three closely synergistic research projects and an integrated...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart | June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
pediatric cardiomyopathy, management, clinical outcomes, NIH study, Circulation Heart Failure, Children's Hospital of Michigan
News | Congenital Heart | April 04, 2017
A multi-center study done in the United States and Canada may have global applicability for families with children...
Philips, Phoenix Children's Hospital, strategic partnership, congenital heart
News | Congenital Heart | March 07, 2017
Philips and Phoenix Children’s Hospital (Arizona) announced a long-term strategic partnership with a total value of up...
Jaheim Whigham, Lurie Children's Hospital of Chicago, Syncardia 50cc Total Artificial Heart, youngest patient

At 11 years old, Jaheim Whigham (center) is the youngest and smallest patient to receive the 50cc SynCardia temporary Total Artificial Heart. (Photo: Jan Terry, Ann & Robert H. Lurie Children's Hospital of Chicago)

News | Congenital Heart | January 31, 2017
To save the life of an 11-year-old boy, Ann & Robert H. Lurie Children’s Hospital of Chicago has become the first...
congenital heart disease, CHSD, Society of Thoracic Surgeons, public reporting, parent preferences
News | Congenital Heart | January 25, 2017
Survival statistics, surgeon-specific experience and complication rates are the types of information most wanted by...
Overlay Init